Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Ginkgo Biloba | Modafinil | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 120-240 mg/day of standardized extract (24% flavone glycosides, 6% terpene lactones) divided into 2-3 doses | 100-200 mg once daily (for educational context only — prescription medication in most jurisdictions) |
| Timing | With or without food. Split into 2-3 doses throughout the day. Effects may take 4-6 weeks to manifest. | Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours. |
| Cycle Duration | Ongoing; no cycling required. Clinical trials typically run 22-26 weeks. | Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use). |
| Evidence Level | strong_human | strong_human |
Standardized extract (EGb 761) contains flavonoid glycosides (24%) and terpene lactones (6% — ginkgolides A/B/C and bilobalide) that act through multiple pathways: potent free radical scavenging and inhibition of membrane lipid peroxidation; antagonism of platelet-activating factor (PAF) via ginkgolides; enhancement of cerebral blood flow through nitric oxide-mediated vasodilation and reduced blood viscosity; and increased prefrontal dopamine and acetylcholine release via acylated flavonol glycosides. Bilobalide provides direct neuroprotection against excitotoxicity and mitochondrial dysfunction.
120-240 mg/day of standardized extract (24% flavone glycosides, 6% terpene lactones) divided into 2-3 doses
With or without food. Split into 2-3 doses throughout the day. Effects may take 4-6 weeks to manifest.
Ongoing; no cycling required. Clinical trials typically run 22-26 weeks.
Atypical eugeroic (wakefulness-promoting agent) that primarily inhibits the dopamine transporter (DAT), increasing extracellular dopamine in the prefrontal cortex and nucleus accumbens. This primary action cascades through multiple systems: indirect activation of orexinergic neurons in the lateral hypothalamus via potentiation of glutamatergic transmission; downstream stimulation of histaminergic neurons in the tuberomammillary nucleus (via orexin-mediated disinhibition of GABAergic inputs); and enhancement of norepinephrine release in the locus coeruleus. The net effect is broad-spectrum arousal without the peripheral sympathomimetic effects of classical stimulants.
100-200 mg once daily (for educational context only — prescription medication in most jurisdictions)
Early morning to avoid insomnia; 1 hour before desired peak alertness. With or without food (food slows absorption by ~1 hour but does not reduce bioavailability). Half-life is approximately 12-15 hours.
Not typically cycled in clinical use. Some off-label users cycle to maintain sensitivity (5 days on, 2 off; or as-needed use).
Fast buy links (we may earn a small commission at no extra cost).
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →